Introduction Major depressive disorder (MDD) is a common severe mental disorder,
requiring a tailored and integrated treatment. Several approaches are available including …

Introduction: Major depressive disorder (MDD) is a chronic and debilitating condition often
characterized by inadequate treatment. Notwithstanding the availability of more than a …

Introduction: Major depressive disorder (MDD) remains one of the most prevalent mental
health conditions. It is a chronic, relapsing condition and despite multiple treatment options …

The chronic course of major depressive disorder (MDD) often impedes the ability of patients
to achieve full remission. Return of full functioning is a critical goal of antidepressant …

Background: Major depressive disorder (MDD) is a common, seriously impairing illness.
Desvenlafaxine (administered as desvenlafaxine succinate) is the third serotonin …

Objective: Desvenlafaxine is the third serotonin-norepinephrine reuptake inhibitor (SNRI)
approved by the US Food and Drug Administration for major depressive disorder (MDD) …

Objective: To assess the efficacy, safety, and tolerability of 50-and 100-mg/day doses of
desvenlafaxine (administered as desvenlafaxine succinate), a serotonin-norepinephrine …

Desvenlafaxine (DESV) is a newer antidepressant, which inhibits serotonin-norepinephrine
reuptake neurotransmission, similarly to venlafaxine, milnacipran and duloxetine. It was …

Introduction: The safety and tolerability profiles of antidepressants can often influence the
treatment choices of clinicians treating major depressive disorder. The purpose of this …

Desvenlafaxine (DVS) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a
different pharmacokinetic and pharmacodynamic profile to venlafaxine. It was approved in …